Two-Pronged attack on prostate tumors before removal
NCT ID NCT00329043
Summary
This study tested whether adding the drug sunitinib to standard hormone therapy could better shrink or control prostate tumors before surgical removal. It involved 64 men with high-risk prostate cancer who were scheduled for prostate surgery. Researchers gave participants both treatments for up to 3 months before their planned operation to see if this combination improved outcomes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.